BALMORE PARK SURGERY — All Prescriptions & Medications — Page 13

Practice Code: K81014 | READING, RG4 7SS

Showing results 601-650 of 665

MedicationItems (12m) ↓QuantityCostvs National
Zonisamide131,400£1.2K-70.2% ▼
Levodopa/carbidopa/entacapone132,600£856-53.5% ▼
Glucagon1317£504-14.5% ▼
Testosterone enantate1313£419+82.0% ▲
Sodium fluoride13711£71-60.8% ▼
Powder 3.7 kcal/g energy and protein fortifier (0913081)13420£975+108.4% ▲
Hydrocortisone13130£92+400.6% ▲
Pilocarpine hydrochloride132,128£991+21.0% ▲
Gamolenic acid132,184£528+25.9% ▲
1321£128-63.6% ▼
1320£122-26.7% ▼
1311.9K£1.1K-65.9% ▼
1321£94-68.1% ▼
13630£2.8K+54.0% ▲
Budesonide12867£1.5K-23.4% ▼
Co-tenidone (Atenolol/chlortalidone)12560£41-42.5% ▼
Ephedrine hydrochloride12672£3.0K+60.6% ▲
Bilastine12360£69+144.5% ▲
Midazolam hydrochloride1249£1.1K-16.7% ▼
Buprenorphine hydrochloride12406£280-98.1% ▼
Canagliflozin12360£447-91.6% ▼
Bromocriptine12644£1.2K+80.9% ▲
Triptorelin1212£2.5K-43.1% ▼
Oral rehydration salts12908£319-58.5% ▼
Powder 3:1 formula (0913181)1225.5K£3.7K+98.1% ▲
Prednisolone sodium phosphate12480£311-5.9% ▼
Timolol and travoprost1230£110-62.9% ▼
12511£66-69.6% ▼
1212£130+20.0% ▲
12180£345-42.4% ▼
12900£2.8K-1.5% vs avg
12360£1.7K-2.1% ▼
12700£2.9K-2.1% ▼
12300£2.1K+18.1% ▲
Cimetidine11690£62-41.0% ▼
Minoxidil11648£92-1.3% vs avg
Repaglinide112,980£276-54.5% ▼
Propylthiouracil11476£45-12.5% ▼
Sevelamer11930£151-49.8% ▼
Powder infant formula (0913231)1113.2K£1.9K+43.2% ▲
Chlohexidine gluconate (Emollient)112,750£39+169.4% ▲
Pimecrolimus11330£206-35.0% ▼
Clindamycin/tretinoin11330£125-6.3% ▼
11140£290+128.4% ▲
1125£2.0K+29.6% ▲
11330£108-85.8% ▼
Phosphates (Rectal)1060£696-18.2% ▼
Linaclotide10308£393-45.3% ▼
Dalteparin sodium10284£2.3K-39.5% ▼
Tinzaparin sodium10192£780-32.5% ▼
← Back to BALMORE PARK SURGERY
Data sourced from NHSBSA English Prescribing Dataset, CQC, and GP Patient Survey. Prescribing data does not indicate quality of care. Higher prescribing rates may reflect patient demographics. Always consult your GP for medical advice.